Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Cytarabine

Review the clinical trials studying cytarabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 107

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 198 locations
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 179 locations
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients with High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Status: Active
Location: 186 locations
Comparing Cytarabine + Daunorubicin Therapy versus Cytarabine + Daunorubicin + Venetoclax versus Venetoclax + Azacitidine in Younger Patients with Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Status: Active
Location: 154 locations
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 195 locations
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Active
Location: 136 locations
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Status: Active
Location: 196 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 116 locations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment with Blinatumomab for Children, Adolescents, and Young Adults with Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 84 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 79 locations
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Status: Active
Location: 34 locations
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Active
Location: 24 locations
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Status: Active
Location: 24 locations
Testing the Addition of an Anti-cancer drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients with Acute Myeloid Leukemia that has Changes in NPM1 or MLL/KMT2A Gene
Status: Active
Location: 21 locations
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Status: Active
Location: 20 locations
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Status: Active
Location: 20 locations
A Study to find the Highest Dose of Imetelstat in Combination with Fludarabine and Cytarabine for Patients with AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Status: Active
Location: 18 locations
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Status: Active
Location: 14 locations
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Active
Location: 13 locations
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Status: Active
Location: 14 locations
Cytarabine or Vinblastine Sulfate and Prednisone in Treating Patients with Langerhans Cell Histocytosis
Status: Active
Location: 10 locations
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Status: Active
Location: 11 locations
Talazoparib in Combination with Chemotherapy for the Treatment of Pediatric Patients with Relapsed or Refractory AML, the PARPAML Trial
Status: Active
Location: 10 locations
Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia
Status: Active
Location: 9 locations
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Status: Active
Location: 10 locations